ACE2 Elevation in Severe COVID-19
Top Cited Papers
Open Access
- 1 May 2021
- journal article
- letter
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 203 (9), 1191-1196
- https://doi.org/10.1164/rccm.202101-0142le
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin-Converting Enzyme InhibitionAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Human recombinant soluble ACE2 in severe COVID-19The Lancet Respiratory Medicine, 2020
- A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin stormeLife, 2020
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19The New England Journal of Medicine, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19The New England Journal of Medicine, 2020
- Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection FractionHypertension, 2019
- Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart FailureJournal of the American College of Cardiology, 2017
- Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infectionsNature Communications, 2014
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005